{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-323706","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2025-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.342025+00:00","generated_at":"2026-05-16T12:46:01.022653+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kalaris Therapeutics raises $50M in oversubscribed private placement; cash runway into Q3 2027","bullets":["Raised ~$50M gross via 4.2M shares at $10.00/share and 800K pre-funded warrants at $9.9999.","Pricing was at a premium to prior 5-day closing price on Nasdaq.","Investors include ADAR1 Capital, Coastlands, Invus, RTW, Samsara BioCapital, Woodline Partners.","Proceeds to advance TH103 for neovascular AMD and for working capital; cash runway to Q3 2027.","Private placement expected to close Dec 19, 2025; registration rights to file after April 1, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-323706","json":"https://secwatch.observer/filing/0001193125-25-323706.json","markdown":"https://secwatch.observer/filing/0001193125-25-323706.md","text":"https://secwatch.observer/filing/0001193125-25-323706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525323706/0001193125-25-323706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525323706/d48530d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:46:01.022653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"182886b1bfc1d651a047dbdfe33f6e92dd1b744e","claim":"Kalaris Therapeutics, Inc. issued pre-funded warrants to purchase 800,000 shares of warrant to certain Investors for $9.9999 per Pre-Funded Warrant.","evidence_excerpt":"pre-funded warrants to purchase 800,000 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a price of $9.9999 per Pre-Funded Warrant","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525323706/0001193125-25-323706-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"pre-funded warrants to purchase 800,000 shares"},{"label":"Purchaser","value":"certain Investors"},{"label":"Consideration","value":"$9.9999 per Pre-Funded Warrant"}],"fact_type":"equity_issuance"},{"claim_id":"1df66e5db98eae880de29c9a41e52b252929ca80","claim":"Kalaris Therapeutics, Inc. issued 4,200,000 shares of common stock to certain institutional accredited investors for $10.00 per Share.","evidence_excerpt":"the Company agreed to issue and sell to the Investors in a private placement an aggregate of 4,200,000 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of $10.00 per Share","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525323706/0001193125-25-323706-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"4,200,000 shares"},{"label":"Purchaser","value":"certain institutional accredited investors"},{"label":"Consideration","value":"$10.00 per Share"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}